Episode Details
Back to Episodes
Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases
Published 5 months, 2 weeks ago
Description
He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.